 SAN DIEGO--BUSINESS WIRE--Gossamer Bio, Inc. Nasdaq: GOSS, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Thursday, February 18, 2021 at 11:00am ET to discuss GB004, its oral HIF-1α stabilizer for the treatment of inflammatory bowel disease IBD, including ulcer 